acalabrutinib + prednisolone

Acalabrutinib + prednisolone is a combination of two pharmaceutical agents used in investigational regimens for the treatment of hematological malignancies, particularly diffuse large B-cell lymphoma (DLBCL). Acalabrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that blocks BTK-mediated signaling in B cells, thereby inhibiting proliferation and survival of malignant B cells. Prednisolone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties; it modulates gene expression to suppress immune responses and inflammation. This combination has been studied as part of multi-agent chemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone), where acalabrutinib replaces or augments standard components to potentially improve efficacy in DLBCL[3][5][6][7].